HOW ONCOLOGY INTELLIGENCE-2013 CAN HELP YOU?
OI2013 is a first interactive report which covers vast and largest updated dataset for cancer treatment molecules with individual company's profiles, holding developmental / marketing rights to these molecules. It also contains oncology focused deals, funding options and technology platforms, established vs. emerging cancer drug targets with complete details and role in cancer, Top companies research strategies, their drift towards cancer indications, market forecast of all major cancer indications with drugs competitive position and much more.
Crystal Clear Intelligence...... Intelligence to Decide & Act......
OI 2013 COVERS:
COMPLETE CANCER CLINICAL PIPELINE (PHI/PHII/PHIII) & LATE PRECLINICAL PIPELINE.
DESCRIPTION OF DRUG TECHNOLOGIES, DRUGS IN DEVELOPMENT WITH TARGETS & CLINICAL TRIAL STATUS.
19 CANCER INDICATIONS (full coverage with market forecast)
TOP 10 COMPANIES DRUG DEVELOPMENT STRATEGIES
1650+ CANCER DRUGS IN DEVELOPMENT
850+ ONCOLOGY FOCUSED DEALS
624 CANCER COMPANIES PROFILES
210+ CANCER DRUG TARGETS
170+ ORPHAN DRUG STATUS
2012 CORPORATE ACTIONS & CLINICAL DRUG DEVELOPMENT UPDATES
Major Advantages with Report:
1st Interactive Report which provides complete picture on oncology drug discovery.
1st Report which clearly de-marks what Top companies development strategies are across cancer drug targets and all cancer
indications with business deals and acquisitions.
1st Report with info graphics representations which can be used in ppts. to make effective presentations.
1st Interactive Report which acts as an complete source book to provide comprehensive picture on cancer drug discovery by eliminating non focused information and is must for any professional linked with oncology rug discovery to keep himself/herself updated in drug discovery.
1st Report where each and every data is validated, and one can check all by effective cross linking within e-copy and outside with valid URL link.
1st Report which is crafted by Team of Scientists and Professionals working on Cancer with inputs directly from Cancer Drug Companies, where ever it was required.
1st Report which is very economically priced, with such amount of data; and is only possible due to direct marketing.
For more benefits and details on OI2013 download
Reports Benefits www.omicsx.com/RB_OI2013.pdf
Table of Content www.omicsx.com/TOC_OI2013.pdf
What OI 2013 Do Not Contains:
To avoid ambiguity OI2013 does not contain any cancer care / cancer pain / cancer management or cancer diagnostic molecules or any such exclusive company profile. Thus helping researchers to compare apples with apples.
OI2013, does not contain any dead/abandoned molecules, or molecules without any active and valid clinical update between Jan 2010 to Dec 2012, thus narrowing down the data.